Real-world study on piperacillin-tazobactam in the treatment of complicated urinary tract infection in adults
- VernacularTitle:哌拉西林/他唑巴坦治疗成人复杂性尿路感染的真实世界研究
- Author:
Yi YANG
1
;
Ming LI
1
;
Na LI
2
;
Zhipeng WEN
1
;
Bing ZHAO
1
Author Information
1. Dept. of Pharmacy，the Affiliated Hospital of Guizhou Medical University，Guiyang 550004，China
2. Institution of Clinical Drug Trial，the Affiliated Hospital of Guizhou Medical University，Guiyang 550004，China
- Publication Type:Journal Article
- Keywords:
piperacillin-tazobactam;
complicated urinary tract infection;
pathogen;
efficacy;
safety
- From:
China Pharmacy
2024;35(14):1753-1758
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the efficacy and safety of piperacillin-tazobactam in the treatment of complicated urinary tract infection （cUTI） in adults. METHODS Retrospective analysis was performed on the data of 352 cUTI adult patients in our hospital from January 1， 2021 to December 31， 2023. All patients received piperacillin-tazobactam. The detection of pathogens in patients， the clinical efficacy and microbial clearance rate after treatment， the occurrence of adverse drug reactions and treatment cost were observed in all patients. RESULTS Of the 352 patients， pathogen culture results of 54 patients were detected， mainly Escherichia coli producing extended-spectrum beta-lactamases. The clinical effective rate was 94.3%， the microbial clearance rate was 81.5%， and the incidence of adverse reactions was 1.4%. The percentage of male effective patients in urinary surgery department was significantly higher than invalid patients， while the proportion of transplant treatment and the proportion of patients with concomitant kidney transplantation were significantly lower than invalid patients （P＜0.05）. There was no significant difference in clinical effective rate between the two groups after those patients were divided into target treatment group and empirical treatment group according to the sensitivity of pathogen to piperacillin-tazobactam （P＝0.902 5）. CONCLUSIONS Piperacillin-tazobactam is effective and safe in the treatment of cUTI.
